The 2020 update of the recommendations of the American Society of Clinical Oncology/College of American Pathology (ASCO/CAP) defines ER-positive BC as samples with 1% or more of tumor nuclei positive for ER expression by validated immunohistochemistry (IHC). This evidence concerns the gene ESR1 and neoplasm.